Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 20 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited announced that its subsidiary Sentynl Therapeutics has received marketing authorization from the UK MHRA for NULIBRY, the first treatment for Molybdenum Cofactor Deficiency Type A. This approval allows access to a critical therapy for an ultra-rare genetic disorder that primarily affects infants. NULIBRY is already approved in the US and has received Orphan Drug status in the UK. The press release emphasizes the significance of this development for patients suffering from this life-threatening condition.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2024, titled "Sentynl Therapeutics receives marketing authorization for NULIBRY?? (fosdenopterin) from the UK MHRA for treatment of MoCD Type A".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases